LifeVantage Corporation (LFVN)

Market Cap	155.72M
Revenue (ttm)	222.35M
Net Income (ttm)	9.15M
Shares Out	12.59M
EPS (ttm)	0.70
PE Ratio	17.65
Forward PE	11.09
Dividend	$0.16 (1.29%)
Ex-Dividend Date	May 30, 2025

Volume	105,400
Open	13.06
Previous Close	13.06
Day's Range	12.31 - 13.17
52-Week Range	5.52 - 27.38
Beta	0.46
Analysts	Strong Buy
Price Target	30.50 (+146.56%)
Earnings Date	Aug 27, 2025

About LFVN

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, and skin and hair care products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduc...

• Industry: Packaged Foods
• Sector: Consumer Staples
• CEO: Steven Fife
• Employees: 222
• Stock Exchange: NASDAQ
• Ticker Symbol: LFVN
• Website: https://www.lifevantage.com

Financial Performance

In 2024, LifeVantage's revenue was $200.16 million, a decrease of -6.20% compared to the previous year's $213.40 million. Earnings were $2.94 million, an increase of 15.63%.

Analyst Summary

According to 2 analysts, the average rating for LFVN stock is "Strong Buy." The 12-month stock price target is $30.5, which is an increase of 146.56% from the latest price.

Price Target

$30.5

(146.56% upside)

Analyst Consensus: Strong Buy